Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts ITCI Hot Sheet
Join SI Premium – FREE
Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.70), $0.14 better than the analyst estimate of ($0.84). Revenue for the quarter came in at $4.36 thousand versus the consensus estimate of $50 thousand.
For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Elon Musk’s trillion-dollar meltdown: How SpaceX and Tesla erased $700 billion
- Community West Bancshares (CWBC) Misses Q2 EPS by 20c
- Gentex Corporation (GNTX) Tops Q2 EPS by 8c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
The Children's Investment Fund (TCI), EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
